Suscribirse

Does curettage–cement packing for treating giant cell tumors at the knee lead to osteoarthritis? - 07/11/17

Doi : 10.1016/j.otsr.2017.06.013 
A. Caubère a, b, , S. Harrosch a, M. Fioravanti a, G. Curvale a, A. Rochwerger a, J.-C. Mattei a
a Service de chirurgie orthopédique, traumatologique et des tumeurs musculo-squelettiques, hôpital Nord, chemin des Bourrely, 13915 Marseille cedex 20, France 
b HIA Sainte-Anne, 26, impasse des Coquelicots, 83210 La Farlède, France 

Corresponding author. HIA Sainte-Anne, 26, impasse des Coquelicots, 83210 La Farlède, France.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Introduction

Giant cell tumors (GCTs) make up 15 to 20% of bone-related tumors in adults. They are often found around the knee in the metaphysis and epiphysis area, contacting the joint cartilage. The aims of our study were to evaluate the presence of early knee osteoarthritis (OA) in patients with GCTs in the knee area treated by curettage–cement packing, and to evaluate whether replacing subchondral bone with acrylic cement has an effect on the functional outcomes and quality of life.

Material and methods

This was a retrospective study of all patients operated between 2000 and 2010 by the same specialized surgical team. Functional outcomes and quality of life were evaluated in each patient using the Knee Injury and Osteoarthritis Outcome (KOOS), the Musculoskeletal Tumor Society Score (MSTS) and the Short Form-36 (SF-36). The presence of OA was evaluated in a full radiological work-up comparing the operated knee with the healthy contralateral knee. Knee OA was defined as grade 3 or grade 4 radiographic findings based on the Kellgren and Lawrence classification, and a significant difference between the operated and contralateral knee.

Results

Nineteen patients were included in this study. The average follow-up was 120 months (range 60–180). Four patients (21%) had radiographic KL-3 and one patient (5%) had KL-4. Eight patients (42%) had recurrence of the GCT. The distance between the tumor and cartilage, and the area of the subchondral bone invaded by the tumor appeared to contribute to OA progression.

Discussion

Resection of GCTs around the knee by curettage–cement packing did not have an effect on development of OA. In the four patients who developed knee OA, the tumor was located less than 3mm from the joint cartilage and took up more than 90% of the epiphysis. Based on these observations, there seems to be a strong correlation between the development of knee OA and the small quantity of subchondral bone left after curettage. The functional outcomes and quality of life were similar no matter the knee OA grade in patients. Replacing subchondral bone by cement had no effect on quality of life in this study.

Level of evidence

IV (retrospective study).

El texto completo de este artículo está disponible en PDF.

Keywords : Giant cell tumors, Curettage, Bone cement, Knee osteoarthritis


Esquema


© 2017  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 103 - N° 7

P. 1075-1079 - novembre 2017 Regresar al número
Artículo precedente Artículo precedente
  • The kinematic alignment technique for TKA reliably aligns the femoral component with the cylindrical axis
  • C. Rivière, F. Iranpour, S. Harris, E. Auvinet, A. Aframian, P. Chabrand, J. Cobb
| Artículo siguiente Artículo siguiente
  • Prediction of muscle strength and postoperative function after knee flexor muscle resection for soft tissue sarcoma of the lower limbs
  • A. Tanaka, Y. Yoshimura, K. Aoki, M. Okamoto, M. Kito, S. Suzuki, A. Takazawa, T. Ishida, H. Kato

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.